Catalent Implements Optofluidic Platform for Cell-Line Development

Article

Catalent Biologics will adopt Berkeley Lights’ Beacon optofluidic platform for its cell-line development workflow.

Catalent Pharma Solutions and Berkeley Lights announced in a July 10, 2018 press release that Catalent Biologics will adopt Berkeley Lights’ Beacon optofluidic platform for its cell-line development workflow.

The Beacon platform is capable of screening thousands of clones in parallel and identifying top-producing clones in five days. According to Catalent, automating the process on the platform provides additional insights into the behavior of clonal populations that are currently unavailable using traditional techniques. 

The four integrated workflows of the platform-import, culture, assay, and export-will be applied to Catalent Biologics’ GPEx cell-line development platform as well as Catalent’s ongoing research and development activities.

Source: Catalent Pharma Solutions

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Preeya Beczek, managing director and co-founder of Beczek.COM, chats about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.
Related Content
© 2025 MJH Life Sciences

All rights reserved.